Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CAR19-tTreg |
Synonyms | |
Therapy Description |
Limited information is currently available on CAR19-tTreg, a putative cell therapy comprising regulatory T-cells expressing an anti-CD19 chimeric antigen receptor (CAR) (Apr 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CAR19-tTreg | CD19 Immune Cell Therapy 62 | Limited information is currently available on CAR19-tTreg, a putative cell therapy comprising regulatory T-cells expressing an anti-CD19 chimeric antigen receptor (CAR) (Apr 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05114837 | Phase Ib/II | CAR19-tTreg Cyclophosphamide + Fludarabine | Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL | Withdrawn | USA | 0 |